Insulet Q1 ’20 Earnings Update
Insulet hosted its Q1 ’20 earnings call and provided updates to its diabetes business including the impact of COVID-19 and timing of the Omnipod Horizon launch. Of note, Insulet has filed the updated Horizon algorithm after the company discovered a software anomaly in early March 2020, leading to the trial being put on hold. Below, FENIX provides highlights and insights from the call.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.